RAC · ASX

Race Oncology Ltd. (ASX:RAC)

AU$3.96

 -0.57 (-12.583%)
ASX:Live
03/10/2025 04:11:39 PM
Volume Spike Near Resistance HALO Price Momentum HALO Ords HALO Consensus Value +5
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RAC Overview

RAC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About RAC

Website

Race Oncology Ltd.

Telephone

61.2.8051.3043

Address

Level 36, Gateway 1 Macquarie Place Sydney, New South Wales (NSW) 2000

Description

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The firm is involved in developing Bisantrene, a small molecule anthracene chemotherapeutic, to address the unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer and acute myeloid leukemia. It is also investigating the impact Bisantrene and new molecules have on the m6A RNA pathway. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

RAC Price Chart

Key Stats

Market Cap

AU$789.38M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.92 - 4.68

Trade Value (12mth)

AU$78,629.00

1 week

44.73%

1 month

227.08%

YTD

230.66%

1 year

168.05%

All time high

4.68

Key Fundamentals

EPS 3 yr Growth

-62.00%

EBITDA Margin

N/A

Operating Cashflow

-$5m

Free Cash Flow Return

-26.70%

ROIC

-27.90%

Interest Coverage

N/A

Quick Ratio

10.30

Other Data

Shares on Issue (Fully Dilluted)

174m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

RAC Announcements

Latest Announcements

Date Announcements

02 October 25

Discovery of the Anticancer Mechanism of (EE)-bisantrene

×

Discovery of the Anticancer Mechanism of (EE)-bisantrene

02 October 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

25 September 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

24 September 25

RC220 IND Approval from Korean MFDS

×

RC220 IND Approval from Korean MFDS

23 September 25

Trading Policy Update

×

Trading Policy Update

18 September 25

Race Oncology Investor Webinar Invitation

×

Race Oncology Investor Webinar Invitation

18 September 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

18 September 25

Race Oncology investor briefing presentation

×

Race Oncology investor briefing presentation

17 September 25

Hong Kong Investor Lunch Briefing Details

×

Hong Kong Investor Lunch Briefing Details

16 September 25

Race Breakthrough Composition of Matter IP Discovery

×

Race Breakthrough Composition of Matter IP Discovery

11 September 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

02 September 25

First Hong Kong Site Activated for RC220 Trial

×

First Hong Kong Site Activated for RC220 Trial

02 September 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

26 August 25

Appendix 4E & Annual Report

×

Appendix 4E & Annual Report

26 August 25

Corporate Governance Statement

×

Corporate Governance Statement

26 August 25

Appendix 4G

×

Appendix 4G

04 August 25

Phase 2 Bisantrene AML Trial Results Published

×

Phase 2 Bisantrene AML Trial Results Published

24 July 25

Notification regarding unquoted securities - RAC

×

Notification regarding unquoted securities - RAC

23 July 25

June 2025 Quarterly Activity Report and Appendix 4C

×

June 2025 Quarterly Activity Report and Appendix 4C

15 July 25

Race Oncology Upcoming 2025 Investor Events

×

Race Oncology Upcoming 2025 Investor Events

10 July 25

RC220 Human Ethics Approvals Received in Hong Kong

×

RC220 Human Ethics Approvals Received in Hong Kong

26 June 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

19 June 25

First Patient Safely Combine Dosed in Phase 1 RC220 Trial

×

First Patient Safely Combine Dosed in Phase 1 RC220 Trial

19 June 25

Application for quotation of securities - RAC

×

Application for quotation of securities - RAC

17 June 25

Termination of City of Hope Global IP License

×

Termination of City of Hope Global IP License

RAC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.08 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.08 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.6 -36.1 66.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.07 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.07 -0.06 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -12.3 -29.2 75.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.4 -3.2 -2.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.16 0.11 0.09 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.14 0.09 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.1 -33.7 -14.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 161 165 172 Lock Lock Lock
Basic m Lock Lock Lock Lock 161 165 172 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 13 18 10 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -13 -18 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.4 -38.1 43.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -13 -18 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -13.1 -37.3 43.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -13 -18 -10 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -4 -5 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -10 -14 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 11.4 -39.3 65.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -11 -10 -5 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -1 5 1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -11 -10 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.2 10.4 52.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 22 17 14 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 27 20 17 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -22 -17 -14 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 25 18 16 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 25 18 16 Lock Lock Lock
     Growth % Lock Lock Lock Lock -29.4 -28.1 -12.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -37.3 -68.3 -27.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -38.9 -75.5 -29.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -42.2 -81.4 -59.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -32.2 -63.1 -27.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -34.6 -43.6 -26.7 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.7 1.0 1.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -84.4 -93.9 -85.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 20.4 9.3 10.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 20.4 9.3 10.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 91.4 98.7 91.4 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -924.8 -511.0 -314.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -37.3 -68.3 -27.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -38.9 -75.5 -29.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -38.9 -75.5 -29.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 955.5 1,192.4 1,075.1 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -955.5 -1,192.4 -1,075.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.02%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RAC Shortsell

Frequently Asked Questions

The current share price of Race Oncology Ltd. (RAC:ASX) is AU$3.96.
The 52-week high share price for Race Oncology Ltd. (RAC:ASX) is AU$4.68.
The 52-week low share price for Race Oncology Ltd. (RAC:ASX)? is AU$0.92.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) has a franking level of 0.0%.
Race Oncology Ltd. (RAC:ASX) is classified in the Healthcare.
The current P/E ratio for Race Oncology Ltd. (RAC:ASX) is .
The current share price of Race Oncology Ltd. (RAC:ASX) is AU$3.96.
The 52-week high share price for Race Oncology Ltd. (RAC:ASX) is AU$4.68.
The 52-week low share price for Race Oncology Ltd. (RAC:ASX)? is AU$0.92.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) does not pay a dividend.
Race Oncology Ltd. (RAC:ASX) has a franking level of 0.0%.
Race Oncology Ltd. (RAC:ASX) is classified in the Healthcare.
The current P/E ratio for Race Oncology Ltd. (RAC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff